≈98% of commercial prurigo nodularis (PN) patients (18+ years of age) nationally are covered for DUPIXENT. ≈91% of commercial PN patient lives have to fail only 1 or 2 prescription topical treatments.^3,a

^aMMIT Analysis, June 2025. Analysis included DUPIXENT, tralokinumab, upadacitinib, abrocitinib, lebrikizumab, and nemolizumab.